Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 25,761 shares at $60.00 ($1.5M) on 2021-11-10, disclosed to the SEC on 2021-11-12.
Open-market sale of $1.5M KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.00 | 15,900 | $954K | 61.8% |
| 2 | $58.73 | 739 | $43K | 2.8% |
| 3 | $59.78 | 4,561 | $273K | 17.7% |
| 4 | $59.78 | 4,561 | $273K | 17.7% |
| Total | $59.89 avg | 25,761 | $1.5M | 100% |
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |